Phase 3
N=114
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
Chronic Allograft Nephropathy · Chronic Kidney Disease · Chronic Renal Failure · Disordered Mineral Metabolism · End Stage Renal Disease
Bottom Line
View on ClinicalTrials.gov: NCT00975000 ↗Enrolled (actual)
114
Serious AEs
29.8%
Results posted
Jan 2016
Primary outcome: Primary: Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) — 3.5; 78.9 percentage of participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Cinacalcet (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Amgen
- Primary completion
- Sep 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) |
3.5; 78.9 | <0.001 sig |
| SECONDARY Percent Change From Baseline to Week 52 in Bone Mineral Density at the Femoral Neck |
1.05; 1.24 | 0.266 |
| SECONDARY Change From Baseline to the EAP in Mean Serum Phosphorus |
0.07; 0.52 | <0.001 sig |
| SECONDARY Change From Baseline to Week 52 in eGFR |
0.06; -0.37 | 0.842 |
| SECONDARY Change From Baseline to the EAP in Corrected Total Calcium |
-0.14; -1.53 | <0.001 sig |
| SECONDARY Change From Baseline to the EAP in Intact Parathyroid Hormone (iPTH) |
-10.6; -127.9 | 0.002 sig |
| SECONDARY Change From Baseline to the EAP in Urine Phosphorus |
-1.47; -2.62 | 0.846 |
| SECONDARY Percentage of Participants With a Parathyroidectomy |
0.0; 0.0 | — |
| SECONDARY Time to Parathyroidectomy |
— | — |
Summary
Hyperparathyroidism (HPT) is common in people with a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the neck. Patients with HPT can develop bone disease (osteodystrophy). This bone disease can cause bone pain, fractures, and poor formation of red blood cells. Other problems from HPT may include increases in blood levels of calcium (hypercalcemia) and low blood levels of phosphorus (hypophosphatemia). The high calcium levels may cause calcium to deposit in body tissues. Calcium deposits can cause arthritis (joint pain and swelling), muscle inflammation, itching, gangrene (death of soft tissue), heart and lung problems or kidney transplant dysfunction (worsening of kidney transplant function). The purpose of this study is to evaluate the effects of cinacalcet (Sensipar/Mimpara) on high calcium levels in the blood in patients with HPT after a kidney transplant.
Eligibility Criteria
Inclusion Criteria
- Received a kidney transplant ≥ 9 weeks at time of Screening and ≤ 24 months before first dose
- May be the first kidney transplant or a repeat kidney transplant.
- Subjects with a functional, stable kidney transplant, defined as MDRD estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² (chromic kidney disease stage 3 or better) at Screening.
- Men or women ≥ 18 years at the start of Screening (ie, time of informed consent).
- Corrected total serum calcium > 10.5 mg/dL (2.63 mmol/L), defined as the mean of 2 values in Screening period.
- iPTH > 100 pg/mL (10.6 pmol/L), during the Screening period (obtained at either Screen 1 or Screen 2).
Exclusion Criteria
- Received cinacalcet therapy post-transplant for more than 14 days cumulatively post-transplant. If cinacalcet therapy was received for a total of 14 days or less post-transplant, there must be a 4-week washout before subject is eligible for screening (Note: This does not exclude pre-transplant use of cinacalcet).
- Anticipated parathyroidectomy within 6 to12 months after Randomization.
- Ongoing therapy with bisphosphonates or use within 6 months prior to Screening.
- Ongoing use of 1, 25-dihydroxyvitamin D3 (including other active vitamin D metabolites or analogues) or use within 30 days prior to Screening.
- Ongoing use of calcium supplements or use within 30 days prior to Screening.
- Ongoing use of phosphate binders (calcium or non-calcium containing) or use within 30 days prior to Screening.
- Ongoing use of a thiazide diuretic.
- Subjects with a history of seizures who had a seizure within the 3 months prior to Randomization, which required adjustments to the seizure medication.
- Acute Kidney Injury (AKI) or renal biopsy within 6 weeks prior to Screening, unless it is an institutional protocol-driven biopsy.
Data sourced from ClinicalTrials.gov (NCT00975000). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.